Novartis (AG) ADR (NYSE:NVS) and Qualcomm, Inc.’s (NASDAQ:QCOM) subsidiary Qualcomm Life, announced a collaboration regarding the development of Novartis’ Breezhaler inhaler device. It is a digital inhaler for patients suffering from chronic obstructive pulmonary disease (COPD).
The Breezhaler (TM) inhaler will provide them compliance with the facility of accessing the data of their usage. It will consist of a device that can detect and report the usage to the patient as well as physician. The device is integrated with the patient’s smart phone and Novartis COPD mobile application.
The application will transmit the data to the company’s COPD cloud. With the help of the data, the physician will be able to monitor the extent of obstruction.The device is very easy to handle with no assembly requirement. The drug maker is planning to launch the device in 2019.
GBI Research has released its latest research report stating: “Chronic Obstructive Pulmonary Disease (COPD) Market to 2019 – Highly-Priced New Combination Products Forecast to Capture Significant Market Share and Drive Growth”
Globally, the COPD market value is $11.3 billion. It is expected to touch $15.6 billion by 2019. Many companies have COPD-related drugs in their drug pipeline. The drug makers are working very diligently to develop COPD medicines with patient compliance. This segment will take much share of the COPD market till 2019 due to their effectiveness, easy to operate, and patent expiration of traditional drugs.
The pipeline drugs include long-acting LABA/LAMA once a day fixed-dose combinations such as QVA-149, umeclidinium bromide/vilanterol, and olodaterol/tiotropium.
COPD has two subtypes; chronic bronchitis and emphysema. In 2011, approximately 10 million Americans suffered from chronic bronchitis among which 70% of the patients were above age 45. Around 4.7 million Americans had an attack of emphysema in the same time, 90% population reported be above 45.
Globally more than three million people died of COPD in 2012. The main COPD prevalence area is low-income group population.
GlaxoSmithKline has a market share of $129 million in 2014 with their product of Relvar/Breo and Anoro. AstraZeneca’s Eklira has gained a share of $25 million in 2014.
The COPD portfolio is very hefty and robust. It includes Ultibro Breezhaler (indacaterol/glycopyrronium bromide), Seebri® Breezhaler® (glycopyrronium bromide), and Onbrez® Breezhaler®/ArcaptaTM NeohalerTM (indacaterol).
ANALYST’S VIEW ABOUT COPDMARKET:
GBI Research Senior Analyst Yasser Mushtaq said in a report: “Currently, the market is dominated by three brands, namely Pfizer’s Spiriva, GlaxoSmithKline’s (GSK’s) Advair and AstraZeneca’s Symbicort, which have all generated multi-billion dollar revenues to date.
He further added: “The patents for these leading brands have either expired or will do very soon, leaving the market open to generic competition, which will impact negatively on these brands’ sales figures.”
I am David, economist, originally from Britain, and studied in Germany and Canada. I am now living in the United States. I have a house in Ontario, but I actually never go. I wrote some books about sovereign debt, and mortgage loans. I am currently retired and dedicate most of my time to fishing. There were many topics in personal finances that have currently changed and other that I have never published before. So now in Business Finance, I found the opportunity to do so. Please let me know in the comments section which are your thoughts. Thank you and have a happy reading.